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BACKGROUND: Women are two times more likely to be diagnosed with depression than men. Sex hormones
modulating serotonergic transmission are proposed to partly underlie these epidemiologic ﬁndings. Here, we used
the cross-sex steroid hormone treatment of transsexuals seeking sex reassignment as a model to investigate acute
and chronic effects of testosterone and estradiol on serotonin reuptake transporter (SERT) binding in female-to-male
and male-to-female transsexuals.
METHODS: Thirty-three transsexuals underwent [11C]DASB positron emission tomography before start of treatment,
a subset of which underwent a second scan 4 weeks and a third scan 4 months after treatment start. SERT
nondisplaceable binding potential was quantiﬁed in 12 regions of interest. Treatment effects were analyzed using
linear mixed models. Changes of hormone plasma levels were correlated with changes in regional SERT
nondisplaceable binding potential.
RESULTS: One and 4 months of androgen treatment in female-to-male transsexuals increased SERT binding in
amygdala, caudate, putamen, and median raphe nucleus. SERT binding increases correlated with treatment-induced
increases in testosterone levels, suggesting that testosterone increases SERT expression on the cell surface.
Conversely, 4 months of antiandrogen and estrogen treatment in male-to-female transsexuals led to decreases in
SERT binding in insula, anterior, and mid-cingulate cortex. Increases in estradiol levels correlated negatively with
decreases in regional SERT binding, indicating a protective effect of estradiol against SERT loss.
CONCLUSIONS: Given the central role of the SERT in the treatment of depression and anxiety disorders, these
ﬁndings may lead to new treatment modalities and expand our understanding of the mechanism of action of
antidepressant treatment properties.
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TranssexualISShttp://dx.doi.org/10.1016/j.biopsych.2014.09.010It is commonly suggested that the uneven sex distribution in
the prevalence and clinical presentation of mood and anxiety
disorders is universal. Women are approximately twice as
likely to be diagnosed with depression and anxiety disorders
as men (1,2). In addition, women exhibit earlier age at onset of
depression, a greater number of depressive symptoms, and a
greater number of episodes (3). Several biological and psy-
chological mechanisms potentially underlying these epidemio-
logic ﬁndings have been discussed. Although self-report bias,
gender-role stereotypes, and sociocultural norms may con-
found effects of these mechanisms (1,2), a strong case has
been made for the effect of sex differences in coping styles
and response to stress (4,5), as well as in genetic and
endocrine inﬂuences. Indeed, many women experience
depressive symptoms in periods of hormonal ﬂuctuationsN: 0006-3223 Biolog
SEE COMMENTAsuch as with menses, during and after pregnancy, or during
perimenopausal transition (6–8).
Within the last 15 years, an increasing amount of molecular
imaging studies using positron emission tomography
(PET) have examined serotonergic key proteins such as the
serotonin reuptake transporter (SERT) and serotonergic recep-
tors in depressed versus healthy subjects (9–11). In a recent
meta-analysis, we reported reduced SERT expression of about
10% in major depression and that severity of depression was
associated with SERT reduction in the amygdala (12). In line
with the above-mentioned epidemiologic ﬁndings, several
studies also suggested sex-speciﬁc abnormalities in the
expression of the SERT (13–16) or the serotonin 1A receptor
(17,18). Moreover, several PET studies also indicated gender
differences in regional protein binding in the healthy human& 2015 Society of Biological Psychiatry 525
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However, whether sex hormones directly or indirectly play a
role in the underlying cause of these abnormalities remains
unknown.
Still, animal and human studies provided evidence for an
important interplay between gonadal hormones and the seroto-
nergic system. While human data have often applied merely
correlational approaches (26–29), hormone treatment of ovariec-
tomized animals has provided convincing evidence of
a more causal relationship between sex hormones and seroto-
nergic neurotransmission (30–33). Early data indicated that
testosterone or estradiol treatment is associated with increased
density of serotonin reuptake sites [reviewed by Bethea et al.
(31)], a ﬁnding that has been replicated more recently and shown
to be mediated by nuclear estrogen receptors (34). This is in
agreement with reduced SERT density in ovariectomized mice, in
which estradiol levels are low (32). In contrast, low estradiol levels
in the same animals were associated with increased regional
SERT activity, which, in turn, concurs with rapid reductions of 5-
HT uptake in neuronal cell lines after estradiol treatment (35).
Taken together, animal studies point toward a strong
inﬂuence of gonadal hormones on SERT expression and
function, whereas human data are almost absent and only
correlational in nature. Direct experimental approaches, in
which independent variables are effectively manipulated and
their impact on dependent variables is observed, have yet to
be performed. Investigating the effects of chronic steroid
hormone treatment in subjects with gender identity disorder
provides such an experimental approach. These subjects are
seeking life-long treatment with high dosages of cross-sex
steroid hormones to adjust their physical appearance to their
gender identity. Thus, testosterone is used when seeking
masculinization (progestins are sometimes added to stop
menstrual bleeding), while estrogens are administered to
achieve feminization together with antiandrogens (e.g., cypro-
terone acetate), which block testosterone binding to androgen
receptors but also show strong antigonadotrophic properties.
We aimed to investigate SERT binding using PET and the
radioligand [11C]DASB in transsexual subjects before and
during cross-sex steroid hormone treatment. Based on the
animal data presented above, we hypothesized that testoster-
one, as well as estradiol treatment, will increase SERT binding
and that treatment-induced increases in hormone plasma
levels will correlate with increases in SERT binding. For
comparison, a group of healthy female and male control
subjects receiving no treatment was further included.
METHODS AND MATERIALS
Subjects
The study sample consisted of 33 transsexual subjects and 35
control subjects: 14 female-to-male (FtM) and 19 male-to-
female (MtF) transsexuals, 11 female control subjects (FC),
and 24 male control subjects (MC). Transsexuals were recruited
from the Transgender outpatient unit of the Department of
Obstetrics and Gynecology, Medical University of Vienna. They
were naive to steroid hormone treatment and were seeking sex
reassignment. Transsexuals reported gender dysphoria since a
relatively early age (before or at puberty). Mean age was526 Biological Psychiatry October 15, 2015; 78:525–533 www.sobp.onumerically lower in FtM (28.21 6 6.81, mean 6 SD) compared
with MtF (31.79 6 9.21), FC (30.43 6 10.07) and MC (34.14 6
11.00), although this difference was not signiﬁcant (p 5 .38,
analysis of variance). To rule out internal medicine and neuro-
logical disorders, subjects underwent a standard medical
examination including electrocardiogram, routine laboratory
tests, and the Structural Clinical Interview for DSM-IV Disorders.
Further exclusion criteria included intake of psychotropic
medication within 6 months before inclusion, past or current
substance abuse, pregnancy, and hormonal treatment before
study participation. Diagnostic assessment of transsexualism
followed DSM-IV-TR and ICD-10 and was performed after
several semi-structured, sociodemographic, clinical, and psy-
chiatric interviews based on legal requirements for cross-sex
hormonal treatment in Austria. Psychotherapy before and
during hormone treatment was also recommended. After at
least 1 year of hormone therapy, subjects could decide to
undergo sex reassignment surgery (36). The recommendations
in Austria are largely based on the Standards of Care for the
Health of Transsexual, Transgender, and Gender Nonconform-
ing People, The World Professional Association for Transgender
Health, 7th Version, Atlanta, Georgia, 2011. Therefore, none of
our study participants had sex reassignment surgery before or
during study participation. However, two FtM and one MtF
already had their ofﬁcial names changed at screening visit.
Written informed consent was obtained after thorough explan-
ation of the study to the subjects. Data from a subsample of
subjects (14 MtF, 9 FC, and 13 MC) have been published in a
previous study (24). The study was approved by the Ethics
Committee of the Medical University of Vienna.
Study Design and Treatment Protocol
The study was designed as a longitudinal monocenter study.
Fourteen FtM and 19 MtF transsexuals underwent a baseline
scan before start of hormone treatment (PET 1). Scans of 11 FC
and 24 MC served as control measurements, while 8 of the 24
MC were measured twice to determine the test-retest reliability
of [11C]DASB (time interval: 10.13 6 9.66 days). Baseline scans
in FtM and those in FC were performed irrespective of their
menstrual cycle phase. A subset of transsexuals underwent a
second scan (PET 2; 9 FtM, 16 MtF) 4 weeks after treatment
start, and a third scan (PET 3; 11 FtM, 13 MtF) 4 months after
treatment start. Hormone treatment followed protocols routinely
implemented at the Department of Obstetrics and Gynecology,
Unit for Gender Identity Disorder, at the Medical University of
Vienna. FtM received 1000 mg testosterone undecanoate every
12 weeks (Nebido 250 mg/mL, 4 mL vial, intramuscular; Bayer,
Vienna, Austria). Two cases further received 10 mg to 15 mg
lynestrenol (Orgametril 5 mg, oral; Organon, Oss, The Nether-
lands) daily. MtF received either daily 50 mg cyproterone
acetate (Androcur 50 mg tablet, oral; Bayer; 14 subjects) or
triptorelin acetate 4.12 mg/month (Decapeptyl 172 mg powder
for suspension for injection subcutaneous or intramuscular;
Ferring Arzneimittel, Vienna, Austria; 4 subjects). Additionally,
MtF over 40 years of age received daily doses of 100 μg
estradiol (transdermal therapeutic system applied twice a week;
Estradot, Novartis, Vienna, Austria/Estramon, Hexal, Vienna,
Austria; 3 subjects), while those less than 40 years of age
received 4 mg/day estradiol hemihydrate (Estrofem 2 mg, oral;rg/journal
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subjects received estradiol hemihydrate .75 mg/day to 1.5 mg/
day (Estro-Gel .75 mg/1.25 g/day, transdermal; Meda, Vienna,
Austria). Because of extensive hair loss, six MtF further received
2.5 mg/day of the 5-alpha reductase inhibitor ﬁnasteride (5 mg,
oral; Ratiopharm, Vienna, Austria). One MtF terminated the
study prematurely, moved out of town after the baseline PET,
and received no medication at our hospital.
Serum Sampling
Blood samples were collected before PET scanning for trans-
sexuals at each visit. The analysis of plasma levels of estradiol,
testosterone, and progesterone was done by the Department
of Laboratory Medicine, Medical University of Vienna, Austria
(http://www.kimcl.at).
Positron Emission Tomography
All PET scans were performed in a GE Advance full-ring scanner
(General Electric Medical Systems, Milwaukee, Wisconsin) in
three-dimensional mode at the Department of Biomedical
Imaging and Image-Guided Therapy, Division of Nuclear Med-
icine, Medical University of Vienna. A 5-minute transmission
scan was done using retractable 68Ge rod sources for tissue
attenuation correction (24,37). Data acquisition started simulta-
neously with a bolus injection of [11C]DASB measuring brain
radioactivity in a series of 50 consecutive time frames. Mean
injected dose and speciﬁc activity were not signiﬁcantly differ-
ent between groups at any time point (t test, p . .05; Table 1).
Total acquisition time was 90 minutes. Collected data were
reconstructed in volumes consisting of 35 transaxial sections
(128 3 128 matrix) using a fourier rebinning iterative ﬁltered
back-projection algorithm with a spatial resolution of 4.36 mm
full-width at half maximum 1 cm next to the center of the ﬁeld of
view; for radiotracer preparation and radiochemical variables,
see Lanzenberger et al. (38) and Haeusler et al. (39).
Quantitative Analysis and Regions of Interest
Following between-frame motion correction, individual
summed PET images were spatially normalized to a PET
template in stereotactic Montreal Neurological Institute space
using SPM8 (Wellcome Trust Centre for Neuroimaging,Table 1. Plasma Hormone Levels Before, After 4 Weeks, and Aft
and Antiandrogen and Estrogen Treatment in MtF Transsexuals
FtM
PET 1 PET 2 PET 3
n 14 9 11
T ng/mL .65 6 .86 3.76 6 2.06a 6.37 6 2.
E2 pg/mL 74.00 6 46.80 83.89 6 83.0 60.73 6 25
P ng/mL 3.44 6 5.00 2.83 6 3.90 .79 6 .3
ID MBq/kg 306.76 6 45.98 322.15 6 53.83 333.31 6 58
SA GBq/mmol 13.90 6 13.33 18.22 6 13.77 19.83 6 18
Values represent means 6 SD. Radiochemical variables injected dose an
time point, assessed using t tests.
E2, estradiol; FtM, female-to-male; ID, injected dose; MtF, male-to-fema
activity; T, testosterone.
aIndicates signiﬁcant difference from PET 1, p , .05 corrected.
Biological PsycLondon, United Kingdom; http://www.ﬁl.ion.ucl.ac.uk/spm/).
The SERT nondisplaceable binding potential (BPND) (40) was
quantiﬁed using the multilinear reference tissue model (41).
Cerebellar gray matter (excluding vermis and venous sinus)
was used as reference region, as postmortem and in vivo
SERT quantiﬁcation identiﬁed the cerebellar gray matter as
optimal reference region for [11C]DASB (42,43). All modeling
calculations were performed using PMOD image analysis
software, version 3.3 (PMOD Technologies Ltd, Zurich, Swit-
zerland; www.pmod.com). SERT BPND was computed in a
region of interest (ROI) based approach. Twelve ROIs were
selected including the insula; anterior, middle, and posterior
cingulate cortex; hippocampus; amygdala; hypothalamus;
caudate; putamen; thalamus; and dorsal and median raphe
nucleus. ROIs were based on the automated anatomical
labeling brain atlas (44), except for dorsal and median raphe
nuclei, which were deﬁned manually according to Kranz et al.
(45). ROIs were selected based on their moderate to high
concentration of SERT BPND (46,47), the overlap between sex
steroid receptor distribution and adequate SERT BPND (48,49),
and because of gender-speciﬁc SERT BPND abnormalities in
mood disorders (13,15).
Statistics
Treatment-induced hormone level changes were assessed
using linear mixed models analysis with group (FtM, MtF) and
time (PET 1–3) as ﬁxed factors and subjects as the random
factor, followed by separate models for each group and post
hoc pairwise comparisons, corrected for multiple comparisons
using the Bonferroni procedure. Similarly, changes in regional
SERT BPND over time were assessed using linear mixed models
with group as the between-subjects factor, time and ROI as
repeated factors adjusted for baseline values, and subjects as
the random factor. Associations between treatment-induced
hormonal changes and changes in regional SERT BPND were
calculated using Pearson product-moment correlations. This
was followed by exploratory partial correlations to correct for
initial hormone level (e.g., testosterone) and for changes of
other hormones (e.g., estradiol or progesterone). The signiﬁ-
cance level was set at 5% in all analyses. SPSS version 19.0 for
Windows (SPSS Inc., Chicago, Illinois; www.spss.com) was
used for statistical analysis.er 4 Months of Testosterone Treatment in FtM Transsexuals
MtF
PET 1 PET 2 PET 3
19 16 13
84a 4.38 6 1.47 .53 6 1.28a .58 6 1.37a
.55 26.68 6 12.56 82.94 6 46.07a 89.00 6 62.35a
8 .61 6 .22 .46 6 .20 .43 6 .16a
.82 346.48 6 66.75 351.43 6 49.77 345.46 6 57.61
.50 25.00 6 19.97 19.53 6 17.07 16.84 6 30.84
d speciﬁc activity were not signiﬁcantly different between groups at any
le; P, progesterone; PET, positron emission tomography; SA, speciﬁc
hiatry October 15, 2015; 78:525–533 www.sobp.org/journal 527




Estradiol, testosterone, and progesterone plasma levels at
each time point and plasma level changes between time
points were normally distributed for each group (assessed
using Kolmogorov-Smirnov test and visual inspection). As
expected, androgen treatment in FtM and antiandrogen and
estrogen treatment in MtF had profound effects on hormone
plasma levels, revealed by a signiﬁcant interaction group 3
time (testosterone: F2,38.5 = 67.74, p , .001; estradiol: F2,53.6 =
5.92, p = .005; progesterone: F2,27.2 = 4.41, p = .022).
Androgen treatment in FtM led to signiﬁcant changes in
testosterone (F2,14.1 = 27.94, p , .001) with post hoc pairwise
comparisons revealing increases from PET 1 to PET 2
(p = .005), PET 1 to PET 3 (p , .001), and a trend for PET 2
to PET 3 (p = .086). Conversely, antiandrogen and estrogen
treatment in MtF led to signiﬁcant decreases of testosterone
(F2,26 = 42.21, p , .001), when comparing PET 1 to PET 2 (p ,
.001) and PET 1 to PET 3 (p , .001) but not when comparing
PET 2 to PET 3 (p . .1). Estradiol plasma levels did not change
over the course of treatment in FtM (F2,12.81 = .64, p = .541),
but they profoundly changed in MtF (F2,17.89 = 16.90, p ,
.001), showing signiﬁcant increases from PET 1 to PET 2 (p =
.001) and PET 1 to PET 3 (p = .011) but not from PET 2 to PET
3 (p . .1, all p corrected). Progesterone plasma levels showed
a trend toward decreased values over time in FtM (F2,10.3 =
3.16, p = .085), whereas reductions were signiﬁcant in MtF
(F2,28.4 = 3.95, p = .031) with post hoc tests revealing a
signiﬁcant decrease from PET 1 to PET 3 (p = .034, corrected;
Table 1).
SERT BPND
SERT BPND at each time point and BPND changes between
time points were normally distributed for each region and
group. The comparison between transsexuals and healthy
control subjects revealed signiﬁcantly higher SERT BPND in
MC compared with FtM, whereas no other group comparisons
showed signiﬁcant differences (for further information, see
Supplement 1). Testing the effect of treatment in transsexuals
revealed a signiﬁcant main effect of time (F2,872.3 5 12.14,
p , .001), group (F1,335.6 5 4.13, p 5 .043), and ROI (F11,854.4
5 7.09, p , .001) as well as signiﬁcant interactions for time 3
goup (F2,872.3 5 19.13, p , .001), time 3 ROI (F22,858.8 5 3.23,
p , .001), and time 3 group 3 ROI (F22,858.8 5 2.03, p 5 .004).
To interpret the three-way interaction with respect to
potential group differences, post hoc two-sample t tests for
group comparisons were made for each time point and region.
This revealed that most regions in MtF had numerically higher
BPND values compared with FtM at all three time points.
However, only in the amygdala at baseline, the higher BPND in
MtF was signiﬁcant at an uncorrected level of p 5 .037. To
interpret the three-way interaction with respect to treatment
effects, separate models were calculated for each group and
region, followed by post hoc pairwise comparisons of the
three time points. These analyses revealed a signiﬁcant
increase in SERT BPND over time in FtM in the amygdala
(p 5 .002), caudate (p 5 .002), putamen (p 5 .009), and
median raphe nucleus (p 5 .045) and a trend for hippocampus528 Biological Psychiatry October 15, 2015; 78:525–533 www.sobp.o(p 5 .080), thalamus (p 5 .053), and dorsal raphe nucleus (p 5
.053) (Figure 1). However, when correcting for the number of
performed tests, only changes in amygdala and caudate
remained signiﬁcant.
In contrast to FtM transsexuals, MtF transsexuals exhibited
a decrease of SERT BPND over the course of 4 months in the
insula (p 5 .023) and anterior and mid-cingulate cortex
(p 5 .002 and p 5 .015, respectively) and a trend for putamen
(p 5 .068), with changes only in anterior cingulate cortex
surviving correction for multiple testing (see Table 2 for estimated
means 6 SE and post hoc pairwise comparisons). Controlling for
individualized treatment regimens did not change the main
ﬁndings (further information can be found in Supplement 1).
In the subsample of eight MC, no signiﬁcant differences
were present between the two measurements and test-retest
reliability was high (intraclass correlation coefﬁcient . .8;
Supplement 1).
Associations between Hormonal Changes and
Changes in SERT BPND
The signiﬁcant treatment-induced increase in testosterone
plasma levels in FtM showed strong positive correlations with
changes in regional SERT BPND after 4 weeks of treatment (PET
1 vs. PET 2; Figure 2A). That is, increases in testosterone
plasma levels correlated with increases in SERT BPND in
anterior cingulate cortex (p 5 .027), amygdala (p 5 .010),
caudate (p 5 .001), putamen (p 5 .001), and thalamus
(p 5 .015) and a trend for median raphe nucleus (p 5 .053).
No signiﬁcant correlations were observed in other regions,
indicating a regional effect. Controlling for baseline testosterone
levels and changes in estradiol plasma levels in separate partial
correlation analyses reduced the p value to a nonsigniﬁcant
trend for the anterior cingulate cortex (p 5 .075 and p 5 .076,
respectively) but did not change the signiﬁcance of results in
other regions. Likewise, controlling for changes in progesterone
plasma levels had no signiﬁcant effect. However, correlations
between testosterone and SERT BPND became nonsigniﬁcant
when correlating hormonal changes with changes in SERT
BPND after 4 months of treatment (PET 1 vs. PET 3).
In contrast to the results in FtM, treatment-induced decreases
in testosterone plasma levels and increases in estradiol plasma
levels in MtF after 4 weeks of treatment (PET 1 vs. PET 2) were
not correlated with changes in SERT BPND in any of the
investigated brain regions. Partial correlation analyses did not
change the results. However, correlating signiﬁcant estradiol
changes after 4 months of treatment (PET 1 vs. PET 3) with
changes in regional SERT BPND (PET 1 vs. PET 3) showed
positive associations in the insula (p 5 .006), mid-cingulate
cortex (p 5 .032), hippocampus (p 5 .048), and putamen
(p 5 .046) (Figure 2B). When controlling for progesterone plasma
levels, signiﬁcances increased for insula (p 5 .004) and mid-
cingulate (p5 .026) but decreased to a trend for hippocampus (p
5 .079) and putamen (p 5 .063). Signiﬁcant correlations were
also observed when comparing values after 4 weeks with those
after 4 months of treatment (PET 2 vs. PET 3) in insula (p 5 .027)
and mid-cingulate cortex (p 5 .020) in regions that also showed
a signiﬁcant decrease in SERT BPND (Table 2).
Finally, Pearson product-moment correlations revealed no
signiﬁcant associations between depressive symptoms andrg/journal
Figure 1. Line chart showing changes in serotonin transporter (SERT)
binding potential (BPND) and plasma levels of testosterone and estradiol in
female-to-male and male-to-female transsexuals over the course of cross-
sex steroid treatment. Depicted are means 6 95% conﬁdence interval at
positron emission tomography (PET) 1, i.e., baseline (BL), after 4 weeks (4w)
of treatment at PET 2, and after 4 months (4m) of treatment at PET 3.
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time point (for clinical characteristics, see text and Table S1 in
Supplement 1).DISCUSSION
In this study, we found that testosterone treatment in FtM
transsexuals signiﬁcantly increased SERT BPND after 1 month
as well as after 4 months of treatment in regions with adequate
signal-to-noise ratio, i.e., moderate to high SERT density
(Figure 1, Table 2). Early animal studies demonstrated that,
in contrast to 5α-dihydrotestosterone, a nonaromatizable
androgen, testosterone increased SERT density and SERT
messenger RNA in rats (50). While 5α-dihydrotestosterone
cannot be converted to estrogen by aromatase, testosterone
action is suggested to depend in part on its conversion to
estradiol. Furthermore, brain masculinization is believed to
depend on organizational effects of estrogen, triggered by
aromatized testosterone, to which the initially undifferentiated
brain is exposed (51). We therefore suggest that testosterone
treatment in FtM affected SERT binding via aromatization to
estradiol and activation of estrogen receptors.
Plasma testosterone levels rose progressively over the
course of treatment in FtM. Correspondingly, our data show
a progressive increase in SERT BPND from subchronic testo-
sterone administration (4 weeks) to long-term effects
(4 months). Furthermore, acute increases in SERT BPND (after
4 weeks) in anterior cingulate cortex, amygdala, caudate,
putamen, and thalamus were found to be positively correlated
with changes in plasma testosterone levels. However, no
correlations were observed after 4 months of treatment (PET
1 vs. PET 3). If one assumes a causal relationship, this
apparent loss of SERT dependency on testosterone levels
after 4 months of treatment therefore points to ceiling effects
of the inﬂuence of testosterone levels.
In contrast to SERT BPND increases in FtM after testoster-
one treatment, regional SERT BPND in MtF remained constant
after the ﬁrst 4 weeks of estrogen and antiandrogen treatment.
However, values signiﬁcantly decreased after 4 months of
treatment in anterior and mid-cingulate cortex and insula,
whereas hormonal levels signiﬁcantly changed only within
the ﬁrst 4 weeks after treatment start. Assuming that the
effects of testosterone on SERT density depend on its
conversion to estradiol, SERT BPND should remain constant
when reducing testosterone levels while increasing those of
estradiol, which is in accordance with our data. The signiﬁcant
decrease of regional SERT BPND after 4 months of treatment,
on the other hand, warrants a different explanation that
apparently exceeds estradiol effects on SERT BPND. Still,
negative associations between estradiol increase and regional
SERT BPND downregulation after 4 months of treatment
showed that regional SERT BPND decreased to a lesser extent
when estradiol level increases were larger. In other words,
estradiol increases seemed to have a protective effect against
SERT BPND loss.
Our results indicate increases in SERT BPND when testo-
sterone (and aromatized estradiol) increases. According to a
simple mechanistic view on SERT function, elevated SERThiatry October 15, 2015; 78:525–533 www.sobp.org/journal 529
Table 2. Changes in Serotonin Transporter Binding Potentials over Time in 12 A Priori Regions of Interest in FtM and MtF
Transsexuals
FtM MtF
PET 1 PET 2 PET 3 PET 1 PET 2 PET 3
n 14 9 11 19 16 13
INS .31 6 .04 .33 6 .04 .35 6 .04 .38 6 .03 .41 6 .03 .35 6 .03c
ACC .24 6 .02 .26 6 .02 .25 6 .03 .23 6 .03 .26 6 .03 .20 6 .02b,c
MCC .17 6 .03 .18 6 .03 .17 6 .04 .16 6 .03 .17 6 .03 .12 6 .03c
PCC .10 6 .02 .12 6 .02 .12 6 .02 .07 6 .02 .08 6 .01 .05 6 .01
HIP .34 6 .04 .38 6 .03 .42 6 .04a .46 6 .03 .48 6 .03 .45 6 .03
AMY 1.27 6 .07 1.39 6 .06 1.58 6 .07b,c 1.42 6 .09 1.52 6 .11 1.38 6 .09
HYP 1.91 6 .08 1.94 6 .07 2.18 6 .12a 1.93 6 .11 2.04 6 .11 1.87 6 .10
CAUD .48 6 .03 .51 6 .03 .59 6 .03b,c .52 6 .05 .58 6 .05 .47 6 .05c
PUT 1.08 6 .05 1.14 6 .05 1.23 6 .05a,c 1.18 6 .06 1.23 6 .06 1.13 6 .06c
THAL 1.02 6 .05 1.07 6 .05 1.14 6 .05a 1.05 6 .06 1.12 6 .06 1.04 6 .06
DRN 2.63 6 .20 2.55 6 .21 3.33 6 .31a,c 3.10 6 .21 3.46 6 .26 3.36 6 .36
MRN 2.13 6 .21 2.51 6 .20b 3.09 6 .39a 2.48 6 .17 2.90 6 .22 2.64 6 .16
Values are estimations based on the mixed models analyses and represent means 6 SE at baseline (PET 1), 4 weeks after (PET 2), and 4 months
after (PET 3) start of cross-sex steroid hormone treatment.
ACC, anterior cingulate cortex; AMY, amygdala; CAUD, caudate; DRN, dorsal raphe nucleus; FtM, female-to-male; HIP, hippocampus; HYP,
hypothalamus; INS, insular cortex; MCC, middle cingulate cortex; MRN, median raphe nucleus; MtF, male-to-female; PCC, posterior cingulate
cortex; PET, positron emission tomography; PUT, putamen; THAL, thalamus.
a,bIndicates signiﬁcant changes from PET 1.
c,dIndicates signiﬁcant changes from PET 2.
a,cPost hoc pairwise comparisons are uncorrected.
b,dPost hoc pairwise comparisons corrected at p , .05.
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reduced extracellular serotonin. Furthermore, according to
the serotonin hypothesis of depression, serotonin deﬁciency
is considered a hallmark underlying depressive symptoms.530 Biological Psychiatry October 15, 2015; 78:525–533 www.sobp.oThus, SERT BPND may be expected to be high in depressed
subjects (16,52,53), which is, however, in contrast to our meta-
analysis showing SERT reductions in several regions (12).
Furthermore, studies indicate that testosterone supplementa-Figure 2. Scatter plots depicting
associations between the change
in serotonin reuptake transporter
(SERT) binding potential (BP) and
in plasma steroid hormones for (A)
female-to-male (FtM) and (B) male-
to-female (MtF) transsexuals. Scat-
tered lines represent 95% conﬁ-
dence intervals. Positive asso-
ciations between changes in SERT
BP in amygdala, caudate, and puta-
men and testosterone plasma level
increase within the ﬁrst 4 weeks
(4w) of treatment (baseline [BL] 2
4w) were found in FtM transsexuals
(upper row). Positive associations
between changes in SERT BP in
insula, mid-cingulate, and putamen
and estradiol plasma level increase
over the course of 4 months (4m) of
treatment (BL 2 4m) were found in
FtM transsexuals (bottom row). PET,
positron emission tomography.
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well as in surgically menopausal women (54,55), and prelimi-
nary data indicate that short-term estradiol treatment may
qualify as an effective therapy for perimenopausal major
depression (56). Recent animal research indicates that andro-
gen therapy elevates serotonin levels and that this is depend-
ent on aromatase activity (57). Accordingly, exogenous
androgen increases aromatization to estradiol, which leads
to increases in serotonin synthesis and availability via estrogen
receptors (58). Furthermore, according to the use it or lose it
hypothesis formulated by Ramamoorthy et al. (59), SERT cell
surface expression is increased in response to increased
synaptic serotonin. Conversely, SERT proteins are downregu-
lated when 5-HT levels are low. Taken together, our data
indicate that testosterone treatment in FtM increased seroto-
nin levels, which thereby increased SERT expression. With
reference to depression, our interpretations are still very
speculative since no associations were found between
depressive symptoms and regional SERT BPND. Future
research should investigate testosterone-induced changes of
serotonergic neurotransmission and the potential beneﬁts of
testosterone as add-on therapy to selective serotonin reup-
take inhibitor treatment in major depression.
Our study includes limitations that compromise the interpre-
tation of its results. First, our results in transsexual subjects
cannot easily be generalized to other human studies. According
to Swaab and Garcia-Falgueras (60), transsexuality may derive
from a mismatch between sex differentiation of the brain and of
the body. Transsexual subjects exhibit features in brain struc-
ture and function that reﬂect their gender identity rather than
their genetic sex (24,61–63). However, they may also exhibit
features that are speciﬁc to their condition, which can include
the neural underpinnings of well-being, self-esteem, and psy-
chological strain (64–66). We cannot exclude that these char-
acteristics include alterations within the serotonergic system.
However, when comparing transsexuals with their sex-matched
control subjects (e.g., FtM with FC and MtF with MC), there was
no signiﬁcant difference in regional SERT BPND. This is in
accordance with our previous publication (24), a ﬁnding which
can be explained by the overlap in study participants between
the current and the previous study. On the other hand, in the
current study, MC had signiﬁcantly higher SERT BPND than FtM
in several regions. This is in accordance with Jovanovic et al.
(19), showing decreased BPND in women compared with men,
but in disagreement with Erritzoe et al. (20), showing the
opposite pattern in the midbrain.
Second, reductions of testosterone in most MtF are
achieved by inhibition of the negative diencephalic pituitary
testicular feedback system by the antiandrogen cyproterone
acetate. This drug exhibits a close structural relationship with
progestogens; therefore, we cannot exclude a more direct
effect that goes beyond the modulation of testosterone levels.
Indeed, progesterone levels decreased over time in MtF. Still,
when correlating changes in testosterone plasma levels with
those in SERT BPND, correction for progesterone changes did
not inﬂuence the results. However, correction affected the
relation between estradiol and SERT BPND changes.
Third, no arterial blood samples were available to quantify
SERT BPND independent of a reference region. However,
previous studies investigating SERT occupancy using [11C]Biological PsycDASB identiﬁed the cerebellar gray matter as optimal refer-
ence (42,52). Even a 50% difference in cerebellar speciﬁc
binding between subjects would lead to only 3.5% bias for
group comparisons in target regions (52).
Finally, since psychiatric disorders other than transsexuality
were no exclusion criteria, this could have affected SERT
BPND. Indeed, 12 of the 33 transsexuals (4 of 14 FtM and 8 of
19 MtF) were diagnosed with a previous mood or anxiety
disorder (i.e., dysthymic disorder, major depressive disorder in
full or partial remission, or social phobia) according to the
Structural Clinical Interview for DSM-IV Disorders. However,
comparing SERT BPND in subjects with and without a previous
diagnosis, groups did not signiﬁcantly differ.
In conclusion, our data provide evidence that long-term
high-dosage cross-sex steroid hormone treatment in trans-
sexual subjects affects SERT binding in a hormone-speciﬁc
manner. Testosterone treatment increased SERT binding,
whereas chronic antiandrogen treatment decreased it. Given
the central role of the SERT in the treatment of depression and
anxiety disorders, our ﬁndings may lead to new treatment
modalities and understanding of the mechanism of action of
antidepressant treatment properties.ACKNOWLEDGMENTS AND DISCLOSURES
This study was supported by the Austrian National Bank
(OeNB, Anniversary Fund No. 13214) and the Austrian Science
Fund (FWF, No. 23021) to R. Lanzenberger.
We are grateful to D. Winkler, E. Akimova, C. Kraus,
K. Kletter, R. Dudczak, G. Karanikas, E.K. Tempfer-Bentz,
and C. Tempfer for their medical support and to R. Seiger for
support in data analysis. We thank C. Philippe for support in
radiosyntheses and B. Reiterits, I. Leitinger, and R. Bartosch
for PET measurements. We are especially grateful to all
transsexual subjects for participating in this study.
Parts of this study were presented at the 10th International
Symposium on Functional NeuroReceptor Mapping of the
Living Brain, May 21–24, 2014, The Netherlands, and at the
29th International College of Neuropsychopharmacology
World Congress of Neuropsychopharmacology, June 22–26,
2014, Vancouver, Canada, by G.S. Kranz.
All authors declare no competing ﬁnancial interests in
relation to the work described. Without any relevance to this
work, S. Kasper declares that he has received grant/research
support from Bristol Myers-Squibb, Eli Lilly, GlaxoSmithKline,
Lundbeck, Organon, Sepracor, and Servier; has served as a
consultant or on advisory boards for AstraZeneca, Bristol-
Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Lundbeck,
Merck Sharp and Dome, Novartis, Organon, Pﬁzer, Schwabe,
Sepracor, and Servier; and has served on speakers’ bureaus
for Angelini, AstraZeneca, Bristol Myers-Squibb, Eli Lilly,
Janssen, Lundbeck, Pﬁzer, Pierre Fabre, Schwabe, Sepracor,
and Servier. R. Lanzenberger has received travel grants and
conference speaker honoraria from AstraZeneca, Roche, and
Lundbeck A/S. M. Mitterhauser and W. Wadsak have received
speaker honoraria from Bayer. P. Baldinger, M. Spies, and
G.S. Kranz have received travel grants from Roche, AOP
Orphan Pharmaceuticals, and Pﬁzer.
All other authors report no biomedical ﬁnancial interests or
potential conﬂicts of interest.hiatry October 15, 2015; 78:525–533 www.sobp.org/journal 531
Testosterone Increases Serotonin Transporter Binding
Biological
PsychiatryClinicalTrials.gov: Sex Steroids and the Serotonin Trans-
porter; https://clinicaltrials.gov/; NCT01065220.ARTICLE INFORMATION
From the Department of Psychiatry and Psychotherapy (GSK,
MSa, PB, GG, MSp, SK, RL); Department of Biomedical
Imaging and Image-guided Therapy (WW, DH, MM), Division
of Nuclear Medicine; and Department of Obstetrics and
Gynecology (UK), Medical University of Vienna, Austria.
Address correspondence to Rupert Lanzenberger, M.D.,
Medical University of Vienna, Department of Psychiatry and
Psychotherapy, Waehringer Guertel 18-20, Vienna 1090,
Austria; E-mail: rupert.lanzenberger@meduniwien.ac.at.
Received Jun 4, 2014; revised Sep 8, 2014; accepted Sep
8, 2014.
Supplementary material cited in this article is available
online at http://dx.doi.org/10.1016/j.biopsych.2014.09.010.
REFERENCES
1. Kessler RC (2003): Epidemiology of women and depression. J Affect
Disord 74:5–13.
2. Bekker MH, van Mens-Verhulst J (2007): Anxiety disorders: Sex
differences in prevalence, degree, and background, but gender-
neutral treatment. Gend Med 4(suppl B):S178–S193.
3. Smith DJ, Kyle S, Forty L, Cooper C, Walters J, Russell E, et al. (2008):
Differences in depressive symptom proﬁle between males and
females. J Affect Disord 108:279–284.
4. McGuinness TM, Dyer JG, Wade EH (2012): Gender differences in
adolescent depression. J Psychosoc Nurs Ment Health Serv 50:
17–20.
5. Valentino RJ, Reyes B, Van Bockstaele E, Bangasser D (2012):
Molecular and cellular sex differences at the intersection of stress
and arousal. Neuropharmacology 62:13–20.
6. Weissman MM, Olfson M (1995): Depression in women: Implications
for health care research. Science 269:799–801.
7. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR (2004):
Prevalence of depression during pregnancy: Systematic review.
Obstet Gynecol 103:698–709.
8. Llaneza P, Garcia-Portilla MP, Llaneza-Suarez D, Armott B, Perez-
Lopez FR (2012): Depressive disorders and the menopause transition.
Maturitas 71:120–130.
9. Smith DF, Jakobsen S (2009): Molecular tools for assessing human
depression by positron emission tomography. Eur Neuropsychophar-
macol 19:611–628.
10. Savitz JB, Drevets WC (2013): Neuroreceptor imaging in depression.
Neurobiol Dis 52:49–65.
11. Hesselgrave N, Parsey RV (2013): Imaging the serotonin 1A receptor
using [11C]WAY100635 in healthy controls and major depression.
Philos Trans R Soc Lond B Biol Sci 368:20120004.
12. Gryglewski G, Lanzenberger R, Kranz GS, Cumming P (2014): Meta-
analysis of molecular imaging of serotonin transporters in major
depression. J Cereb Blood Flow Metab 34:1096–1103.
13. Cannon DM, Klaver JM, Klug SA, Carlson PJ, Luckenbaugh DA, Ichise
M, Drevets WC (2013): Gender-speciﬁc abnormalities in the serotonin
transporter system in panic disorder. Int J Neuropsychopharmacol 16:
733–743.
14. Maron E, Toru I, Hirvonen J, Tuominen L, Lumme V, Vasar V, et al.
(2011): Gender differences in brain serotonin transporter availability in
panic disorder. J Psychopharmacol 25:952–959.
15. Staley JK, Sanacora G, Tamagnan G, Maciejewski PK, Malison RT,
Berman RM, et al. (2006): Sex differences in diencephalon serotonin
transporter availability in major depression. Biol Psychiatry 59:40–47.
16. Ruhe HG, Booij J, Reitsma JB, Schene AH (2009): Serotonin trans-
porter binding with [123I]beta-CIT SPECT in major depressive532 Biological Psychiatry October 15, 2015; 78:525–533 www.sobp.odisorder versus controls: Effect of season and gender. Eur J Nucl
Med Mol Imaging 36:841–849.
17. Sullivan GM, Ogden RT, Oquendo MA, Kumar JS, Simpson N, Huang
YY, et al. (2009): Positron emission tomography quantiﬁcation of
serotonin-1A receptor binding in medication-free bipolar depression.
Biol Psychiatry 66:223–230.
18. Szewczyk B, Albert PR, Burns AM, Czesak M, Overholser JC, Jurjus
GJ, et al. (2009): Gender-speciﬁc decrease in NUDR and 5-HT1A
receptor proteins in the prefrontal cortex of subjects with major
depressive disorder. Int J Neuropsychopharmacol 12:155–168.
19. Jovanovic H, Lundberg J, Karlsson P, Cerin A, Saijo T, Varrone A,
et al. (2008): Sex differences in the serotonin 1A receptor and
serotonin transporter binding in the human brain measured by PET.
Neuroimage 39:1408–1419.
20. Erritzoe D, Frokjaer VG, Haahr MT, Kalbitzer J, Svarer C, Holst KK,
et al. (2010): Cerebral serotonin transporter binding is inversely related
to body mass index. Neuroimage 52:284–289.
21. Moses-Kolko EL, Price JC, Shah N, Berga S, Sereika SM, Fisher PM,
et al. (2011): Age, sex, and reproductive hormone effects on brain
serotonin-1A and serotonin-2A receptor binding in a healthy popula-
tion. Neuropsychopharmacology 36:2729–2740.
22. Madsen K, Haahr MT, Marner L, Keller SH, Baare WF, Svarer C, et al.
(2011): Age and sex effects on 5-HT(4) receptors in the human brain: A
[(11)C]SB207145 PET study. J Cereb Blood Flow Metab 31:1475–1481.
23. Lothe A, Boni C, Costes N, Bouvard S, Gorwood P, Lavenne F, et al.
(2010): 5-HT1A gene promoter polymorphism and [18F]MPPF binding
potential in healthy subjects: A PET study. Behav Brain Funct 6:37.
24. Kranz GS, Hahn A, Baldinger P, Haeusler D, Philippe C, Kaufmann U,
et al. (2014): Cerebral serotonin transporter asymmetry in females,
males and male-to-female transsexuals measured by PET in vivo.
Brain Struct Funct 219:171–183.
25. Stein P, Savli M, Wadsak W, Mitterhauser M, Fink M, Spindelegger C,
et al. (2008): The serotonin-1A receptor distribution in healthy men and
women measured by PET and [carbonyl-11C]WAY-100635. Eur J Nucl
Med Mol Imaging 35:2159–2168.
26. Lanzenberger R, Mitterhauser M, Kranz GS, Spindelegger C, Wadsak W,
Stein P, et al. (2011): Progesterone level predicts serotonin-1a receptor
binding in the male human brain. Neuroendocrinology 94:84–88.
27. Moser U, Wadsak W, Spindelegger C, Mitterhauser M, Mien LK,
Bieglmayer C, et al. (2010): Hypothalamic serotonin-1A receptor
binding measured by PET predicts the plasma level of dehydroepian-
drosterone sulfate in healthy women. Neurosci Lett 476:161–165.
28. Jovanovic H, Cerin A, Karlsson P, Lundberg J, Halldin C, Nordstrom AL
(2006): A PET study of 5-HT1A receptors at different phases of the menstrual
cycle in women with premenstrual dysphoria. Psychiatry Res 148:185–193.
29. Jovanovic H, Karlsson P, Cerin A, Halldin C, Nordstrom AL (2009):
5-HT(1A) receptor and 5-HTT binding during the menstrual cycle in
healthy women examined with [(11)C] WAY100635 and [(11)C]
MADAM PET. Psychiatry Res 172:31–37.
30. Rivera HM, Oberbeck DR, Kwon B, Houpt TA, Eckel LA (2009):
Estradiol increases Pet-1 and serotonin transporter mRNA in the
midbrain raphe nuclei of ovariectomized rats. Brain Res 1259:51–58.
31. Bethea CL, Lu NZ, Gundlah C, Streicher JM (2002): Diverse actions of
ovarian steroids in the serotonin neural system. Front Neuroendocrinol
23:41–100.
32. Bertrand PP, Paranavitane UT, Chavez C, Gogos A, Jones M, van den
Buuse M (2005): The effect of low estrogen state on serotonin
transporter function in mouse hippocampus: A behavioral and electro-
chemical study. Brain Res 1064:10–20.
33. Pecins-Thompson M, Brown NA, Bethea CL (1998): Regulation of
serotonin re-uptake transporter mRNA expression by ovarian steroids
in rhesus macaques. Brain Res Mol Brain Res 53:120–129.
34. Sumner BE, Grant KE, Rosie R, Hegele-Hartung C, Fritzemeier KH,
Fink G (2007): Raloxifene blocks estradiol induction of the serotonin
transporter and 5-hydroxytryptamine2A receptor in female rat brain.
Neurosci Lett 417:95–99.
35. Koldzic-Zivanovic N, Seitz PK, Watson CS, Cunningham KA, Thomas
ML (2004): Intracellular signaling involved in estrogen regulation of
serotonin reuptake. Mol Cell Endocrinol 226:33–42.rg/journal
Testosterone Increases Serotonin Transporter Binding
Biological
Psychiatry36. Austrian Government (2014): Recommendations for the Treatment of




37. Lanzenberger RR, Hahn A, Windischberger C, Wadsak W, Holik A,
Gerstl F, et al. (2009): Serotonin-1A receptor binding and reward-
dependent activation are associated within the human dorsal raphe
nucleus as revealed by PET-fMRI. Neuroimage 47:S1–S286.
38. Lanzenberger R, Kranz GS, Haeusler D, Akimova E, Savli M, Hahn A,
et al. (2012): Prediction of SSRI treatment response in major depres-
sion based on serotonin transporter interplay between median raphe
nucleus and projection areas. Neuroimage 63:874–881.
39. Haeusler D, Mien LK, Nics L, Ungersboeck J, Philippe C, Lanzen-
berger RR, et al. (2009): Simple and rapid preparation of [11C]DASB
with high quality and reliability for routine applications. Appl Radiat
Isot 67:1654–1660.
40. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN,
et al. (2007): Consensus nomenclature for in vivo imaging of reversibly
binding radioligands. J Cereb Blood Flow Metab 27:1533–1539.
41. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, et al. (2003):
Linearized reference tissue parametric imaging methods: Application
to [11C]DASB positron emission tomography studies of the serotonin
transporter in human brain. J Cereb Blood Flow Metab 23:1096–1112.
42. Parsey RV, Kent JM, Oquendo MA, Richards MC, Pratap M, Cooper
TB, et al. (2006): Acute occupancy of brain serotonin transporter by
sertraline as measured by [11C]DASB and positron emission tomog-
raphy. Biol Psychiatry 59:821–828.
43. Kish SJ, Furukawa Y, Chang LJ, Tong J, Ginovart N, Wilson A, et al.
(2005): Regional distribution of serotonin transporter protein in post-
mortem human brain: Is the cerebellum a SERT-free brain region?
Nucl Med Biol 32:123–128.
44. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard
O, Delcroix N, et al. (2002): Automated anatomical labeling of
activations in SPM using a macroscopic anatomical parcellation of
the MNI MRI single-subject brain. Neuroimage 15:273–289.
45. Kranz GS, Hahn A, Savli M, Lanzenberger R (2012): Challenges in the
differentiation of midbrain raphe nuclei in neuroimaging research. Proc
Natl Acad Sci U S A 109:E2000.
46. Savli M, Bauer A, Mitterhauser M, Ding YS, Hahn A, Kroll T, et al.
(2012): Normative database of the serotonergic system in healthy
subjects using multi-tracer PET. Neuroimage 63:447–459.
47. Varnas K, Halldin C, Hall H (2004): Autoradiographic distribution of
serotonin transporters and receptor subtypes in human brain. Hum
Brain Mapp 22:246–260.
48. Osterlund MK, Gustafsson JA, Keller E, Hurd YL (2000): Estrogen
receptor beta (ERbeta) messenger ribonucleic acid (mRNA) expres-
sion within the human forebrain: Distinct distribution pattern to
ERalpha mRNA. J Clin Endocrinol Metab 85:3840–3846.
49. Osterlund MK, Keller E, Hurd YL (2000): The human forebrain has
discrete estrogen receptor alpha messenger RNA expression: High
levels in the amygdaloid complex. Neuroscience 95:333–342.
50. McQueen JK, Wilson H, Sumner BE, Fink G (1999): Serotonin trans-
porter (SERT) mRNA and binding site densities in male rat brain
affected by sex steroids. Brain Res Mol Brain Res 63:241–247.Biological Psyc51. Phoenix CH, Goy RW, Gerall AA, Young WC (1959): Organizing action
of prenatally administered testosterone propionate on the tissues
mediating mating behavior in the female guinea pig. Endocrinology 65:
369–382.
52. Meyer JH (2007): Imaging the serotonin transporter during major
depressive disorder and antidepressant treatment. J Psychiatry
Neurosci 32:86–102.
53. Cannon DM, Ichise M, Rollis D, Klaver JM, Gandhi SK, Charney DS,
et al. (2007): Elevated serotonin transporter binding in major depres-
sive disorder assessed using positron emission tomography and
[11C]DASB; comparison with bipolar disorder. Biol Psychiatry 62:
870–877.
54. Sherwin BB, Gelfand MM (1985): Differential symptom response to
parenteral estrogen and/or androgen administration in the surgical
menopause. Am J Obstet Gynecol 151:153–160.
55. Khera M (2013): Patients with testosterone deﬁcit syndrome and
depression. Arch Esp Urol 66:729–736.
56. Cohen LS, Soares CN, Poitras JR, Prouty J, Alexander AB, Shifren JL
(2003): Short-term use of estradiol for depression in perimenopausal
and postmenopausal women: A preliminary report. Am J Psychiatry
160:1519–1522.
57. Bethea CL, Reddy AP, Robertson N, Coleman K (2013): Effects of
aromatase inhibition and androgen activity on serotonin and behavior
in male macaques. Behav Neurosci 127:400–414.
58. Gundlah C, Lu NZ, Mirkes SJ, Bethea CL (2001): Estrogen receptor
beta (ERbeta) mRNA and protein in serotonin neurons of macaques.
Brain Res Mol Brain Res 91:14–22.
59. Ramamoorthy S, Blakely RD (1999): Phosphorylation and sequestra-
tion of serotonin transporters differentially modulated by psychosti-
mulants. Science 285:763–766.
60. Swaab DF, Garcia-Falgueras A (2009): Sexual differentiation of the
human brain in relation to gender identity and sexual orientation.
Funct Neurol 24:17–28.
61. Rametti G, Carrillo B, Gomez-Gil E, Junque C, Segovia S, Gomez A,
et al. (2011): White matter microstructure in female to male trans-
sexuals before cross-sex hormonal treatment. A diffusion tensor
imaging study. J Psychiatr Res 45:199–204.
62. Rametti G, Carrillo B, Gomez-Gil E, Junque C, Zubiarre-Elorza L,
Segovia S, et al. (2011): The microstructure of white matter in male to
female transsexuals before cross-sex hormonal treatment. A DTI
study. J Psychiatr Res 45:949–954.
63. Zhou JN, Hofman MA, Gooren LJ, Swaab DF (1995): A sex difference in
the human brain and its relation to transsexuality. Nature 378:68–70.
64. Luders E, Sanchez FJ, Gaser C, Toga AW, Narr KL, Hamilton LS,
Vilain E (2009): Regional gray matter variation in male-to-female
transsexualism. Neuroimage 46:904–907.
65. Schoning S, Engelien A, Bauer C, Kugel H, Kersting A, Roestel C,
et al. (2010): Neuroimaging differences in spatial cognition between
men and male-to-female transsexuals before and during hormone
therapy. J Sex Med 7:1858–1867.
66. Simon L, Zsolt U, Fogd D, Czobor P (2011): Dysfunctional core beliefs,
perceived parenting behavior and psychopathology in gender identity
disorder: A comparison of male-to-female, female-to-male transsex-
ual and nontranssexual control subjects. J Behav Ther Exp Psychiatry
42:38–45.hiatry October 15, 2015; 78:525–533 www.sobp.org/journal 533
